Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. Three new research papers to help us along our way in general practice this month.

First, how long do modern hip replacements last? How does this new data change our conversation with patients?

Second, it's thought GLP1 agonists could have a role in addiction management, but so far, research has failed to show a definitive benefit. Could new data from the US on veterans with type 2 diabetes show a different picture?

Finally, what analgesia would you recommend for a child in pain? This new paper compared ibuprofen with or without paracetamol or hydromorphone - yes, an extremely potent long-acting opioid for kids. Good idea? We find out.

References

Lancet Hip replacement longevity

Lancet THR Editorial

BMJ GLP1ra and addiction

BJP editorial

JAMA Analgesia and Child

www.nbmedical.com/podcast

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker.Three new pieces of research to talk about in today's podcast.

First, in the NEJM - could patients stop anti-coagulation after ablation for AF? Conventional practice says no. Does this paper change that?

Second, in JAMA - can spinal manipulation, or clinician-guided self-management, or both help with low back pain? This paper is a good crack.

Finally, in the BJGP - what do our patients think about advance care planning? Should we be talking about this more, and, if so, in whom and how?

References

NEJM Anti-coags after ablation in AF

NEJM Editorial

JAMA Low back pain

BJGP Advance care planning

www.nbmedical.com/podcast

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we have three new and interesting research papers to look at.

First, hitting the headlines this week, weight regain after cessation of GLP1 receptor agonists. Not a surprise, perhaps, but how fast does the weight come back, can anything be done to prevent it, and what are the implications for patients and the NHS?

Second, orforglipron - the new GLP1ra on the block and an oral treatment. Can it help weight loss and improvement in cardiometabolic markers in patients with obesity and type 2 diabetes?

Finally, which is better for treating scabies - permethrin or oral ivermectin? Would a tablet be an easier option, or is it just not as good?

References

BMJ Weight regain after cessation of weight loss medications

BMJ Editorial

BMJ Opinion

BMJ Side Effects of GLP1ras

NEJM Orforglipron RCT in obesity

Lancet Orforglipron RCT in obesity and T2DM

BMJ Scabies treatment - ivermectin or permethrin?

PCDS Scabies guideline

BAD Scabies guideline

www.nbmedical.com/podcast